[1]
|
Kandalaft, L.E., Odunsi, K. and Coukos, G. (2019) Immunotherapy in Ovarian Cancer: Are We There Yet? Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 2460-2471. https://doi.org/10.1200/JCO.19.00508
|
[2]
|
Stewart, C., Ralyea, C. and Lockwood, S. (2019) Ovarian Cancer: An Integrated Review. Seminars in Oncology Nursing, 35, 151-156. https://doi.org/10.1016/j.soncn.2019.02.001
|
[3]
|
Armstrong, D.K., Alvarez, R.D., Bakkum-Gamez, J.N., Barroilhet, L., Behbakht, K., Berchuck, A., et al. (2021) Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 19, 191-226. https://doi.org/10.6004/jnccn.2021.0007
|
[4]
|
Hou, J. and Zhu, W. (2020) Research Progress on PD-1/PD-L1 Immune Checkpoint Inhibitors in Ovarian Cancer Treatment. Practical Oncology Journal, 34, 266-270.
|
[5]
|
Li, D. and Zhang, H. (2020) Clinical Research Progress on the Pathogenesis of Ovarian Cancer and Immune Therapy. Practical Journal of Obstetrics and Gynecology, 36, 908-911.
|
[6]
|
Baci, D., Bosi, A., Gallazzi, M., Rizzi, M., Noonan, D.M., Poggi, A., Bruno, A. and Mortara, L. (2020) The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. International Journal of Molecular Sciences, 21, 3125. https://doi.org/10.3390/ijms21093125
|
[7]
|
Whiteside, T.L. (2008) The Tumor Microenvironment and Its Role in Promoting Tumor Growth. Oncogene, 27, 5904-5912. https://doi.org/10.1038/onc.2008.271
|
[8]
|
Di, J., Duiveman-de Boer, T., Figdor, C.G. and Torensma, R. (2013) Aiming to Immune Elimination of Ovarian Cancer Stem Cells. World Journal of Stem Cells, 5, 149-162. https://doi.org/10.4252/wjsc.v5.i4.149
|
[9]
|
Hu, G. and Wang, S. (2017) Tumor-Infiltrating CD45RO(+) Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors. Scientific Reports, 7, Article No. 10376. https://doi.org/10.1038/s41598-017-11122-2
|
[10]
|
Mortenson, E.D., Park, S., Jiang, Z., Wang, S. and Fu, Y.X. (2013) Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19, 1476-1486. https://doi.org/10.1158/1078-0432.CCR-12-2522
|
[11]
|
Singh, M., Loftus, T., Webb, E. and Benencia, F. (2016) Minireview: Regulatory T Cells and Ovarian Cancer. Immunological Investigations, 45, 712-720. https://doi.org/10.1080/08820139.2016.1186689
|
[12]
|
Govindaraj, C., Scalzo-Inguanti, K., Madondo, M., Hallo, J., Flanagan, K., Quinn, M. and Plebanski, M. (2013) Impaired Th1 Immunity in Ovarian Cancer Patients Is Mediated by TNFR2+ Tregs within the Tumor Microenvironment. Clinical Immunology (Orlando, Fla.), 149, 97-110. https://doi.org/10.1016/j.clim.2013.07.003
|
[13]
|
Bu, M., Shen, Y., Seeger, W.L., An, S., Qi, R., Sanderson, J.A. and Cai, Y. (2016) Ovarian Carcinoma-Infiltrating Regulatory T Cells Were More Potent Suppressors of CD8(+) T Cell Inflammation than Their Peripheral Counterparts, a Function Dependent on TIM3 Expression. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 3949-3956. https://doi.org/10.1007/s13277-015-4237-x
|
[14]
|
Winkler, I., Wos, J., Karczmarczyk, A., Miotla, P., Gogacz, M., Skorupska, K., et al. (2020) An Association of Circulating Tregs and Th17 Cells Producing IL-21 and IL-22 with the ROMA in Ovarian Cancer Patients. Cytokine, 134, Article ID: 155194. https://doi.org/10.1016/j.cyto.2020.155194
|
[15]
|
Cannioto, R.A., Sucheston-Campbell, L.E., Hampras, S., Goode, E.L., Knutson, K., Ness, R., et al. (2017) The Association of Peripheral Blood Regulatory T-Cell Concentrations with Epithelial Ovarian Cancer: A Brief Report. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 27, 11-16. https://doi.org/10.1097/IGC.0000000000000845
|
[16]
|
Dutsch-Wicherek, M.M., Szubert, S., Dziobek, K., Wisniewski, M., Lukaszewska, E., Wicherek, L., et al. (2019) Analysis of the Treg Cell Population in the Peripheral Blood of Ovarian Cancer Patients in Relation to the Long-Term Outcomes. Ginekologia Polska, 90, 179-184. https://doi.org/10.5603/GP.2019.0032
|
[17]
|
Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M. and Weaver, C.T. (2005) Interleukin 17-Producing CD4+ Effector T Cells Develop via a Lineage Distinct from the T Helper Type 1 and 2 Lineages. Nature Immunology, 6, 1123-1132. https://doi.org/10.1038/ni1254
|
[18]
|
Park, H., Li, Z., Yang, X.O., Chang, S.H., Nurieva, R., Wang, Y.H., et al. (2005) A Distinct Lineage of CD4 T Cells Regulates Tissue Inflammation by Producing Interleukin 17. Nature Immunology, 6, 1133-1141. https://doi.org/10.1038/ni1261
|
[19]
|
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., et al. (2009) Phenotype, Distribution, Generation, and Functional and Clinical Relevance of Th17 Cells in the Human Tumor Environments. Blood, 114, 1141-1149. https://doi.org/10.1182/blood-2009-03-208249
|
[20]
|
Aotsuka, A., Matsumoto, Y., Arimoto, T., Kawata, A., Ogishima, J., Taguchi, A., et al. (2019) Interleukin-17 Is Associated with Expression of Programmed Cell Death 1 Ligand 1 in Ovarian Carcinoma. Cancer Science, 110, 3068-3078. https://doi.org/10.1111/cas.14174
|
[21]
|
Kusuda, T., Shigemasa, K., Arihiro, K., Fujii, T., Nagai, N. and Ohama, K. (2005) Relative Expression Levels of Th1 and Th2 Cytokine mRNA Are Independent Prognostic Factors in Patients with Ovarian Cancer. Oncology Reports, 13, 1153-1158. https://doi.org/10.3892/or.13.6.1153
|
[22]
|
Hatanaka, H., Abe, Y., Kamiya, T., Morino, F., Nagata, J., Tokunaga, T., et al. (2000) Clinical Implications of Interleukin (IL)-10 Induced by Non-Small-Cell Lung Cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 11, 815-819. https://doi.org/10.1023/A:1008375208574
|
[23]
|
Bais, A.G., Beckmann, I., Lindemans, J., Ewing, P.C., Meijer, C.J., Snijders, P.J. and Helmerhorst, T.J. (2005) A Shift to a Peripheral Th2-Type Cytokine Pattern during the Carcinogenesis of Cervical Cancer Becomes Manifest in CIN III Lesions. Journal of Clinical Pathology, 58, 1096-1100. https://doi.org/10.1136/jcp.2004.025072
|
[24]
|
Zheng, A., Liu, N., Xu, S., Gu, L. and Su, D. (2008) Expression and Clinical Significance of Th1 and Th2 Cytokines in Peripheral Blood of Endometrial Cancer Patients. Chinese Journal of Cancer Clinical Rehabilitation, 187, 938-941.
|
[25]
|
Miller, R.A., Miller, T.N. and Cagle, P.T. (2016) PD-1/PD-L1, Only a Piece of the Puzzle. Archives of Pathology & Laboratory Medicine, 140, 1187-1188. https://doi.org/10.5858/arpa.2016-0252-ED
|
[26]
|
Kim, K.H., Choi, K.U., Kim, A., Lee, S.J., Lee, J.H., Suh, D.S., et al. (2019) PD-L1 Expression on Stromal Tumor-Infiltrating Lymphocytes Is a Favorable Prognostic Factor in Ovarian Serous Carcinoma. Journal of Ovarian Research, 12, 56. https://doi.org/10.1186/s13048-019-0526-0
|
[27]
|
González-Martín, A. and Sánchez-Lorenzo, L. (2019) Immunotherapy with Checkpoint Inhibitors in Patients with Ovarian Cancer: Still Promising? Cancer, 125, 4616-4622. https://doi.org/10.1002/cncr.32520
|
[28]
|
Bellone, S., Buza, N., Choi, J., Zammataro, L., Gay, L., Elvin, J., et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24, 3282-3291. https://doi.org/10.1158/1078-0432.CCR-17-1805
|
[29]
|
Hodi, F.S., Mihm, M.C., Soiffer, R.J., Haluska, F.G., Butler, M., Seiden, M.V., et al. (2003) Biologic Activity of Cytotoxic T Lymphocyte-Associated Antigen 4 Antibody Blockade in Previously Vaccinated Metastatic Melanoma and Ovarian Carcinoma Patients. Proceedings of the National Academy of Sciences of the United States of America, 100, 4712-4717. https://doi.org/10.1073/pnas.0830997100
|
[30]
|
Keung, E.Z., Lazar, A.J., Torres, K.E., Wang, W.L., Cormier, J.N., Ashleigh Guadagnolo, B., et al. (2018) Phase II Study of Neoadjuvant Checkpoint Blockade in Patients with Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma. BMC Cancer, 18, 913. https://doi.org/10.1186/s12885-018-4829-0
|
[31]
|
Heery, C.R., O’Sullivan-Coyne, G., Madan, R.A., Cordes, L., Rajan, A., Rauckhorst, M., et al. (2017) Avelumab for Metastatic or Locally Advanced Previously Treated Solid Tumours (JAVELIN Solid Tumor): A Phase 1a, Multicohort, Dose-Escalation Trial. The Lancet. Oncology, 18, 587-598. https://doi.org/10.1016/S1470-2045(17)30239-5
|
[32]
|
Varga, A., Piha-Paul, S., Ott, P.A., Mehnert, J.M., Berton-Rigaud, D., Morosky, A., et al. (2019) Pembrolizumab in Patients with Programmed Death Ligand 1-Positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028. Gynecologic Oncology, 152, 243-250. https://doi.org/10.1016/j.ygyno.2018.11.017
|
[33]
|
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., et al. (2015) Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients with Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 4015-4022. https://doi.org/10.1200/JCO.2015.62.3397
|
[34]
|
Disis, M.L., Taylor, M.H., Kelly, K., Beck, J.T., Gordon, M., Moore, K.M., et al. (2019) Efficacy and Safety of Avelumab for Patients with Recurrent or Refractory Ovarian Cancer: Phase 1b Results from the JAVELIN Solid Tumor Trial. JAMA Oncology, 5, 393-401. https://doi.org/10.1001/jamaoncol.2018.6258
|
[35]
|
Liu, J.F., Gordon, M., Veneris, J., Braiteh, F., Balmanoukian, A., Eder, J.P., et al. (2019) Safety, Clinical Activity and Biomarker Assessments of Atezolizumab from a Phase I Study in Advanced/Recurrent Ovarian and Uterine Cancers. Gynecologic Oncology, 154, 314-322. https://doi.org/10.1016/j.ygyno.2019.05.021
|
[36]
|
Zamarin, D., Burger, R.A., Sill, M.W., Powell Jr., D.J., Lankes, H.A., Feldman, M.D., et al. (2020) Randomized Phase II Trial of Nivolumab versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 1814-1823. https://doi.org/10.1200/JCO.19.02059
|
[37]
|
Wei, S.C., Duffy, C.R. and Allison, J.P. (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. https://doi.org/10.1158/2159-8290.CD-18-0367
|
[38]
|
Hosseinzadeh, F., Mohammadi, S. and Nejatollahi, F. (2017) Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy. Reports of Biochemistry & Molecular Biology, 6, 8-14.
|
[39]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews. Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[40]
|
Duraiswamy, J., Kaluza, K.M., Freeman, G.J. and Coukos, G. (2013) Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. Cancer Research, 73, 3591-3603. https://doi.org/10.1158/0008-5472.CAN-12-4100
|
[41]
|
Curran, M.A., Montalvo, W., Yagita, H. and Allison, J.P. (2010) PD-1 and CTLA-4 Combination Blockade Expands Infiltrating T Cells and Reduces Regulatory T and Myeloid Cells within B16 Melanoma Tumors. Proceedings of the National Academy of Sciences of the United States of America, 107, 4275-4280. https://doi.org/10.1073/pnas.0915174107
|
[42]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fülop, A., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/NEJMoa1606774
|
[43]
|
Larkin, J., Hodi, F.S. and Wolchok, J.D. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine, 373, 1270-1271. https://doi.org/10.1056/NEJMoa1504030
|
[44]
|
Sharma, P. and Allison, J.P. (2015) The Future of Immune Checkpoint Therapy. Science (New York, N.Y.), 348, 56-61. https://doi.org/10.1126/science.aaa8172
|
[45]
|
Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., et al. (2002) Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease. Nature, 415, 536-541. https://doi.org/10.1038/415536a
|
[46]
|
Xu, Y., Zhang, H., Huang, Y., Rui, X. and Zheng, F. (2017) Role of TIM-3 in Ovarian Cancer. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 19, 1079-1083. https://doi.org/10.1007/s12094-017-1656-8
|
[47]
|
Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., et al. (2005) The Tim-3 Ligand Galectin-9 Negatively Regulates T Helper Type 1 Immunity. Nature Immunology, 6, 1245-1252. https://doi.org/10.1038/ni1271
|
[48]
|
Fucikova, J., Rakova, J., Hensler, M., Kasikova, L., Belicova, L., Hladikova, K., et al. (2019) TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25, 4820-4831. https://doi.org/10.1158/1078-0432.CCR-18-4175
|
[49]
|
Wu, J., Liu, C., Qian, S. and Hou, H. (2013) The Expression of Tim-3 in Peripheral Blood of Ovarian Cancer. DNA and Cell Biology, 32, 648-653. https://doi.org/10.1089/dna.2013.2116
|
[50]
|
Heeren, A.M., Rotman, J., Stam, A.G.M., Pocorni, N., Gassama, A.A., Samuels, S., et al. (2019) Efficacy of PD-1 Blockade in Cervical Cancer Is Related to a CD8(+)FoxP3(+)CD25(+) T-Cell Subset with Operational Effector Functions Despite High Immune Checkpoint Levels. Journal for Immunotherapy of Cancer, 7, 43. https://doi.org/10.1186/s40425-019-0526-z
|
[51]
|
Hiang, Irving, B., Tom, I., Ivelja, S., Refino, C.J., Clark, H., Eaton, D. and Grogan, J.L. (2009) The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells. Nature Immunology, 10, 48-57. https://doi.org/10.1038/ni.1674
|
[52]
|
Oshima, T., Sato, S., Kato, J., Ito, Y., Watanabe, T., Tsuji, I., et al. (2013) Nectin-2 Is a Potential Target for Antibody Therapy of Breast and Ovarian Cancers. Molecular Cancer, 12, 60. https://doi.org/10.1186/1476-4598-12-60
|
[53]
|
Wang, L., Rubinstein, R., Lines, J.L., Wasiuk, A., Ahonen, C., Guo, Y., et al. (2011) VISTA, a Novel Mouse Ig Superfamily Ligand That Negatively Regulates T Cell Responses. The Journal of Experimental Medicine, 208, 577-592. https://doi.org/10.1084/jem.20100619
|
[54]
|
ElTanbouly, M.A., Croteau, W., Noelle, R.J. and Lines, J.L. (2019) VISTA: A Novel Immunotherapy Target for Normalizing Innate and Adaptive Immunity. Seminars in Immunology, 42, Article ID: 101308. https://doi.org/10.1016/j.smim.2019.101308
|
[55]
|
Wang, J., Wu, G., Manick, B., Hernandez, V., Renelt, M., Erickson, C., et al. (2019) VSIG-3 as a Ligand of VISTA Inhibits Human T-Cell Function. Immunology, 156, 74-85. https://doi.org/10.1111/imm.13001
|
[56]
|
Mulati, K., Hamanishi, J., Matsumura, N., Chamoto, K., Mise, N., Abiko, K., et al. (2019) VISTA Expressed in Tumour Cells Regulates T Cell Function. British Journal of Cancer, 120, 115-127. https://doi.org/10.1038/s41416-018-0313-5
|
[57]
|
Grosso, J.F., Kelleher, C.C., Harris, T.J., Maris, C.H., Hipkiss, E.L., De Marzo, A., et al. (2007) LAG-3 Regulates CD8+ T Cell Accumulation and Effector Function in Murine Self- and Tumor-Tolerance Systems. The Journal of Clinical Investigation, 117, 3383-3392. https://doi.org/10.1172/JCI31184
|
[58]
|
Lui, Y. and Davis, S.J. (2018) LAG-3: A Very Singular Immune Checkpoint. Nature Immunology, 19, 1278-1279. https://doi.org/10.1038/s41590-018-0257-1
|
[59]
|
Tu, L., Guan, R., Yang, H., Zhou, Y., Hong, W., Ma, L., Zhao, G. and Yu, M. (2020) Assessment of the Expression of the Immune Checkpoint Molecules PD-1, CTLA4, TIM-3 and LAG-3 across Different Cancers in Relation to Treatment Response, Tumor-Infiltrating Immune Cells and Survival. International Journal of Cancer, 147, 423-439. https://doi.org/10.1002/ijc.32785
|
[60]
|
Liu, J., Blake, S.J., Yong, M.C., Harjunpaa, H., Ngiow, S.F., Takeda, K., et al. (2016) Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discovery, 6, 1382-1399. https://doi.org/10.1158/2159-8290.CD-16-0577
|
[61]
|
Yarchoan, M., Albacker, L.A., Hopkins, A.C., Montesion, M., Murugesan, K., Vithayathil, T.T., et al. (2019) PD-L1 Expression and Tumor Mutational Burden Are Independent Biomarkers in Most Cancers. JCI Insight, 4, e126908. https://doi.org/10.1172/jci.insight.126908
|
[62]
|
Patel, S.P. and Kurzrock, R. (2015) PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 14, 847-856. https://doi.org/10.1158/1535-7163.MCT-14-0983
|
[63]
|
Armstrong, D.K., Alvarez, R.D., Backes, F.J., et al. (2022) NCCN Guidelines® In sights: Ovarian Cancer, Version 3.2022. Journal of the National Comprehensive
Cancer Network (JNCCN), 20, 972-980. https://doi.org/10.6004/jnccn.2022.0047
https://jnccn.org/view/journals/jnccn/20/9/article-p972.xml?print
|
[64]
|
Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P. and Chandra, A.B. (2017) Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 8, 49. https://doi.org/10.3389/fphar.2017.00049
|
[65]
|
Puzanov, I., Diab, A., Abdallah, K., Bingham, C.O., Brogdon, C., Dadu, R., et al. (2017) Managing Toxicities Associated with Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for Immunotherapy of Cancer, 5, 95. https://doi.org/10.1186/s40425-017-0300-z
|